Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 30 April 2012, 12:30 HKT/SGT
Share:
    

Source: A*STAR
Scientists Uncover Exciting Lead into Premature Ageing and Heart Disease

SINGAPORE, Apr 30, 2012 - (ACN Newswire) - Scientists have discovered that they can dramatically increase the life span of mice with progeria (premature ageing disease) and heart disease (caused by Emery-Dreifuss muscular dystrophy) by reducing levels of a protein called SUN1. This research was done by A*STAR's Institute of Medical Biology (IMB) in collaboration with their partners at the National Institute of Allergy and Infectious Diseases in the United States and the Institute of Cellular and System Medicine in Taiwan. Their findings were published in the prestigious scientific journal, Cell, on 27th April 2012 and provide an exciting lead into developing new methods to treat premature aging and heart disease.

Children with progeria suffer symptoms of premature ageing and mostly die in their early teens from either heart attack or stroke. Individuals with Emery-Dreifuss muscular dystrophy (AD-EDMD) suffer from muscle wasting and cardiomyopathy, a type of heart disease that weakens and enlarges the heart muscle making it harder for the heart to pump blood and deliver it to the rest of the body leading to heart failure. Both diseases are caused by mutations in Lamin A, a protein in the membrane surrounding a cell's nucleus which provides mechanical support to the nucleus. SUN1 is a protein also found in the inner nuclear membrane, but there have been no previous studies to show how SUN1 interacts with the Lamin proteins.

The scientists wanted to investigate if SUN1 had any involvement in diseases caused by mutations in Lamin A, so they inactivated SUN1 in mouse models developed for progeria and AD-EDMD. These mouse models for progeria and AD-EDMD usually thrive poorly and have markedly short life spans as they die from premature ageing and heart failure respectively. However, by inactivating SUN1 and reducing SUN1 levels in these mouse models, the scientists observed that the life spans of the mouse models for progeria and AD-EDMD doubled and tripled respectively.

"We actually expected that knocking out Sun1 in these mouse models would worsen their conditions and cause them to die faster but surprisingly we observed the opposite. This is the first time that Sun1 protein has been implicated in diseases linked to Lamin A and it is exciting how basic research has led to a discovery that can potentially have significant impact on us," said Rafidah Abdul Mutalif, who is pursuing her PhD at IMB and one of the main authors of this paper.

Prof. Colin Stewart, Principle Investigator at IMB, said, "Notably, the heart muscle of the mice was restored to near normal function and cardiac function improved when the levels of SUN1 were reduced. Mutations in Lamin A are frequently reported as a cause of heart disease and especially within a group of hereditary cardiomyopathies. This opens up a possibility that from these observations, reduction in SUN1 maybe of therapeutic use for other forms of heart disease. We are very excited about this discovery and look forward to further pursuing this lead which could potentially lead to development of new treatments for heart diseases."

Notes for editor:
The research findings described in this news release can be found in the 27 Apr issue of Cell, Chen, C-Y et al 2012 Accumulation of the Inner Nuclear Envelope Protein Sun1 Is Pathogenic in Progeric and Dystrophic Laminopathies Cell 149.


About the Institute of Medical Biology (IMB)

IMB is one of the Biomedical Sciences Institutes of the Agency for Science, Technology and Research (A*STAR). It was formed in 2007, the 7th and youngest of the BMRC Research Institutes, with a mission to study mechanisms of human disease in order to discover new and effective therapeutic strategies for improved quality of life. From 2011, IMB also hosts the inter-research institute Skin Biology Cluster platform. IMB has 20 research teams of international excellence in stem cells, genetic diseases, cancer and skin and epithelial biology, and works closely with clinical collaborators to target the challenging interface between basic science and clinical medicine. Its growing portfolio of strategic research topics is targeted at translational research on the mechanisms of human diseases, with a cell-to-tissue emphasis that can help identify new therapeutic strategies for disease amelioration, cure and eradication. For more information about IMB, please visit www.imb.a-star.edu.sg.


Contact:
Ms Ong Siok Ming
Senior Officer, Corporate Communications
Agency for Science, Technology and Research
Tel: +65 6826 6254
Email: ong_siok_ming@a-star.edu.sg


Topic: Research and development
Source: A*STAR

Sectors: Science & Research, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



A*STAR
Dec 6, 2022 14:00 HKT/SGT
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
June 2, 2022 21:00 HKT/SGT
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies
June 2, 2022 21:00 HKT/SGT
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies
Sept 30, 2021 16:00 HKT/SGT
A*STAR and Local SME Work with Vaccination Centres to Deploy AVID System for Filling Syringes
July 31, 2020 08:00 HKT/SGT
Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials
July 24, 2020 17:00 HKT/SGT
MP Biomedicals and A*STAR Co-Develop Rapid Antibody Test Kit for SARS-CoV-2
Oct 22, 2019 04:00 HKT/SGT
Fujitsu, SMU and A*STAR Launch Digital Platform Experimentation Project using Quantum-Inspired Computing and Deep Learning Technology
June 28, 2019 08:00 HKT/SGT
Singapore's Drug Development Efforts Given Additional Momentum with National Platforms
Apr 5, 2019 18:00 HKT/SGT
Passing of Dr Sydney Brenner, Nobel Laureate, Renowned Pioneer in Molecular Biology, A*Star Senior Fellow
Jan 21, 2019 13:00 HKT/SGT
Branched-Chain Amino Acids Found to Regulate the Development and Progression of Cancer
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: